Oppenheimer analyst Leland Gershell lowered the firm’s price target on Milestone Pharmaceuticals to $13 from $16 and keeps an Outperform rating on the shares. The firm believes the $125M strategic financing with RTW will provide sufficient capital resources for Milestone to bring etripamil into the early innings of its U.S. launch following anticipated mid-2024 FDA approval as supported by solid Phase 3 data, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MIST:
- Milestone Pharmaceuticals reports Q4 EPS (31c), consensus (33c)
- Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals announces $125M strategic financing
- Milestone Pharmaceuticals progresses in regulatory activities for etripamil
